ArticleAdvances in therapy2026
Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US.
Mehmet A Bilen et al.PubMed ↗Publisher ↗
No numbers read from the abstract.